ICRM
SUPN icon

Insight Capital Research & Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Insight Capital Research & Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-141,485
Closed -$3.5M – 136
2016
Q3 		$3.5M Buy
+141,485
New +$3.2M 1.56% 19

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Insight Capital Research & Management's SUPN Position: Q4 2016 in Review

Insight Capital Research & Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2016, closing a stake of 141,485 shares — an estimated $3.5M sold.

Insight Capital Research & Management first reported a position in SUPN in Q3 2016 and held it in 1 quarter. The position peaked at $3.5M in Q3 2016. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • Insight Capital Research & Management reported no remaining Supernus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Insight Capital Research & Management sold 141,485 Supernus Pharmaceuticals shares in Q4 2016, an estimated $3.5M.
  • Insight Capital Research & Management first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Insight Capital Research & Management's Supernus Pharmaceuticals position peaked at $3.5M in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on Insight Capital Research & Management's 13F filing for Q4 2016, filed 17 Feb 2017.